Journal list menu
Call for Papers
About this Journal
Neuroprotection publishes work centred around the recent advances and breakthroughs in the fields of neuroprotection and central as well as peripheral nervous system repair. This translational neuroscience journal spans fields including neurobiology, neuropharmacology, neurology, neurosurgery, neuroimaging, neurorehabilitation and basic, as well as translational, neuroscience. We’re excited to contribute to the advancement of next-generation treatments for CNS disorders.
Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease
-  21 November 2023
Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review
-  20 November 2023
Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID
-  9 November 2023
Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)
-  21 September 2023
The Alzheimer's Disease Neuroprotection Research Initiative's objective is to facilitate coordinated, multidisciplinary efforts to develop systemic neuroprotective strategies to combat AD. The aim is to achieve mitigation of the full spectrum of pathological processes underlying AD, with the goal of halting or even reversing cognitive decline. The main neuroprotective intervention targets for AD including NTFs, antineuroinflammation, astrocytic protection, remyelination, stem-cell therapy and in vivo neural regeneration, cerebral glucose metabolism regulation, vascular system protection, lymphatic protection, prion-like proteinopathy regulation, peripheral neurotoxic substances clearance, systemic NTFs, and physical exercise, as well as food and nutrition. Investigations into advanced neuroimaging techniques for earlier and more precise characterization of molecular events at scales ranging from cellular to the full system level are equally important as it is necessary for the evaluation of the beneficial effects of different neuroprotective intervention approaches. AD, Alzheimer's disease; CNTF, ciliary neurotrophic factor; DHA, docosahexaenoic acid; GDF11, growth differentiation factor 11; GDNF, glial cell-derived neurotrophic factor; IFN-γ, interferon-γ; NTFs, neurotrophic factors; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-α.
Monocytes in neonatal stroke and hypoxic‐ischemic encephalopathy: Pathophysiological mechanisms and therapeutic possibilities
-  10 August 2023
Monocytes and monocyte-derived cells in hypoxic-ischemic encephalopathy (HIE) and neonatal arterial ischemic stroke (NAIS). (A) The origin of monocytes infiltrating the brain in neonatal HIE and NAIS has yet to be investigated, including the possibility that they originate from various sources, such as the spleen and bone marrow. (B) Monocytes can infiltrate the brain through different routes, but it is not yet known whether they can migrate from the meninges to the brain parenchyma after HIE and NAIS. (C) Monocytes infiltrate the brain in the first hours and days following HIE and NAIS, and chronic monocyte infiltration has been observed in HIE models. Monocytes can differentiate into macrophages and microglia-like cells, which can persist in the brain during the chronic phase of NAIS and HIE.
The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.
Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress
-  21 February 2023
This article review presents hints of how inspiratory O2 manipulations can potentially contribute to enhanced brain function. It thereby provides the ground for exploiting moderate inspiratory plus functional hypoxia to treat individuals with brain disease. Finally, it sketches a planned multistep pilot study in healthy volunteers and first patients, about to start, aiming at improved performance upon motor-cognitive training under inspiratory hypoxia.
Aim & Scope
Meet the Editors-in-Chief
Xun-ming Ji, Capital Medical University, Beijing, China
Professor Xun-ming Ji (MD, PhD, EMBA), being a Chief Physician and Doctorial tutor in neurosurgery, is the President of Beijing Institute of Brain Disorders and the Vice-president of Capital Medical University, China. He is also the Vice-president of International Society on Aging and Disease and the President of American Association of Conditioning Medicine. Based on the theory of blood flow-energy adaptation, his research focuses on developing effective neuroprotective technologies, including normobaric hyperoxia before vascular recanalization, blood flow recanalization conjunctive with targeted hypothermia perfusion, and ischemic conditioning technology. He has more than 500 publications and received several national-level scientific and technological awards, including the second prize of National Science and Technology Progress Award, First Prize of Medical Science of Chinese Medical Association, First Prize of Science and Technology Progress Award of Education Ministry. He has been awarded the China National Distinguished Youth Scientist, the Distinguished Professor of Cheung Kong Scholars Program, and State Council Expert for Special Allowance.
Meet the Editors-in-Chief
Dr. Boltze is a Full Professor of Neuroscience and Principal Investigator at the University of Warwick in Coventry, United Kingdom. Being trained as a physician and neurobiologist and obtaining doctoral degrees in both disciplines, he is interested in cerebrovascular diseases including stroke and vascular dementia. His research is focused on neuroprotection and cell based therapies, taking into consideration translationally relevant aspects such as comorbidities and age. He has published over peer-reviewed 170 journal articles and book chapters, and is listed as an inventor on 7 patents. He is also the president of the International Symposium on Neuroprotection & Neurorepair (ISN&N).
Meet the Editors-in-Chief
Piotr Walczak, MD/PhD, Professor at the Department of Diagnostic Radiology and Nuclear Medicine in University of Maryland, Co-Director of the Program on Image-Guided Neurointerventions (PIGN). He received training in regenerative medicine at the University of South Florida and in molecular and cellular imaging from the Johns Hopkins University. His research program focuses on using multi-modality imaging to improve the delivery of therapeutic agents to the brain in the treatment of stroke, myelin diseases and brain cancer. He has published over 200 articles with a significant impact on his field of research, as evidenced by citation index upwards of 8,000.
Why publish in Neuroprotection?
- Save time formatting your manuscript with Free Formatting submission.
- Your research will be free to access, making it available to read, download and share with ease.
- Quality and impactful research governed by an international and distinguished editorial board.
- Publish open access at no cost to you - fees are waived from 2022-2024.
- An official journal of Chinese Medical Association.
Get the latest research with personalized alert
- Receive personalized alerts at a pace that suits you.
- Keep track of a paper of interest with citation alerts.
- Save content to easily manage your reading list.
- Save searches for instant review later.